カテゴリ： 世界, 医療/バイオ, Market Monitor Global

真性赤血球増加症治療のグローバル市場展望 2023年-2029年：代謝拮抗剤、阻害剤、αインターフェロン、その他

■ 英語タイトル：Polycythemia Vera Treatment Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23LY8574）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23LY8574
■ 発行日：2023年7月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：123
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[真性赤血球増加症治療のグローバル市場展望 2023年-2029年：代謝拮抗剤、阻害剤、αインターフェロン、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の真性赤血球増加症治療市場規模と予測を収録しています。・世界の真性赤血球増加症治療市場：売上、2018年-2023年、2024年-2029年
・世界の真性赤血球増加症治療市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の真性赤血球増加症治療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「代謝拮抗剤」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

真性赤血球増加症治療のグローバル主要企業は、ANP Technologies, INC.、 Bristol-Myers Squibb Company、 F. Hoffmann-La Roche Ltd.、 Galena Biopharma, Inc.、 Gilead Sciences, Inc、 Italfarmaco S.P.A.、 Karus Therapeutics Limited、 Miragen Therapeutics, Inc、 Zydus Cadila Incyte Corp.、 Otsuka America Pharmaceutical, Inc. Pharmaclon、 Teva Pharmaceuticals Inc.、 Schering-Plough、 GNC Vector、 Alfarm、 Merk and Co. Inc.、 Pfizer.、 Novartis AG、 Bayer AG、 Mylan N.V、 GlaxosmithKline plcなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、真性赤血球増加症治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の真性赤血球増加症治療市場：タイプ別、2018年-2023年、2024年-2029年
世界の真性赤血球増加症治療市場：タイプ別市場シェア、2022年
・代謝拮抗剤、阻害剤、αインターフェロン、その他

世界の真性赤血球増加症治療市場：用途別、2018年-2023年、2024年-2029年
世界の真性赤血球増加症治療市場：用途別市場シェア、2022年
・病院薬局、小売薬局、ネット販売

世界の真性赤血球増加症治療市場：地域・国別、2018年-2023年、2024年-2029年
世界の真性赤血球増加症治療市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における真性赤血球増加症治療のグローバル売上、2018年-2023年
・主要企業における真性赤血球増加症治療のグローバル売上シェア、2022年
・主要企業における真性赤血球増加症治療のグローバル販売量、2018年-2023年
・主要企業における真性赤血球増加症治療のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
ANP Technologies, INC.、 Bristol-Myers Squibb Company、 F. Hoffmann-La Roche Ltd.、 Galena Biopharma, Inc.、 Gilead Sciences, Inc、 Italfarmaco S.P.A.、 Karus Therapeutics Limited、 Miragen Therapeutics, Inc、 Zydus Cadila Incyte Corp.、 Otsuka America Pharmaceutical, Inc. Pharmaclon、 Teva Pharmaceuticals Inc.、 Schering-Plough、 GNC Vector、 Alfarm、 Merk and Co. Inc.、 Pfizer.、 Novartis AG、 Bayer AG、 Mylan N.V、 GlaxosmithKline plc

*************************************************************

・調査・分析レポートの概要
真性赤血球増加症治療市場の定義
市場セグメント
世界の真性赤血球増加症治療市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の真性赤血球増加症治療市場規模
世界の真性赤血球増加症治療市場規模：2022年 VS 2029年
世界の真性赤血球増加症治療市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの真性赤血球増加症治療の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の真性赤血球増加症治療製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：代謝拮抗剤、阻害剤、αインターフェロン、その他
真性赤血球増加症治療のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院薬局、小売薬局、ネット販売
真性赤血球増加症治療の用途別グローバル売上・予測

・地域別市場分析
地域別真性赤血球増加症治療市場規模 2022年と2029年
地域別真性赤血球増加症治療売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
ANP Technologies, INC.、 Bristol-Myers Squibb Company、 F. Hoffmann-La Roche Ltd.、 Galena Biopharma, Inc.、 Gilead Sciences, Inc、 Italfarmaco S.P.A.、 Karus Therapeutics Limited、 Miragen Therapeutics, Inc、 Zydus Cadila Incyte Corp.、 Otsuka America Pharmaceutical, Inc. Pharmaclon、 Teva Pharmaceuticals Inc.、 Schering-Plough、 GNC Vector、 Alfarm、 Merk and Co. Inc.、 Pfizer.、 Novartis AG、 Bayer AG、 Mylan N.V、 GlaxosmithKline plc
...

Polycythemia vera is a rare, chronic disorder involving the overproduction of blood cells in the bone marrow (myeloproliferation). The overproduction of red blood cells is most changing, but the production of white blood cells and platelets are also elevated in most cases. Since red blood cells are overproduced in the marrow, this leads to abnormally high numbers of circulating red blood cells within the blood. Consequently, the blood thickens and increases in volume, a condition called hyperviscosity. Thickened blood may not flow through smaller blood vessels properly. A variety of symptoms can occur in individuals with polycythemia vera including nonspecific symptoms such as headaches, fatigue, weakness, dizziness or itchy skin, an enlarged spleen (splenomegaly), a variety of gastrointestinal issues and the risk of blood clot formation, which may prevent blood flow to vital organs such as heart, lungs, kidneys.
This report aims to provide a comprehensive presentation of the global market for Polycythemia Vera Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Polycythemia Vera Treatment. This report contains market size and forecasts of Polycythemia Vera Treatment in global, including the following market information:
Global Polycythemia Vera Treatment Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Polycythemia Vera Treatment Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Polycythemia Vera Treatment companies in 2022 (%)
The global Polycythemia Vera Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Antimetabolite Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Polycythemia Vera Treatment include ANP Technologies, INC., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Galena Biopharma, Inc., Gilead Sciences, Inc, Italfarmaco S.P.A., Karus Therapeutics Limited, Miragen Therapeutics, Inc and Zydus Cadila Incyte Corp., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Polycythemia Vera Treatment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Polycythemia Vera Treatment Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Polycythemia Vera Treatment Market Segment Percentages, by Type, 2022 (%)
Antimetabolite
Inhibitors
Alpha Interferon
Others
Global Polycythemia Vera Treatment Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Polycythemia Vera Treatment Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacies
Retail Pharmacies
Online Sales
Global Polycythemia Vera Treatment Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Polycythemia Vera Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Polycythemia Vera Treatment revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Polycythemia Vera Treatment revenues share in global market, 2022 (%)
Key companies Polycythemia Vera Treatment sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Polycythemia Vera Treatment sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
ANP Technologies, INC.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Galena Biopharma, Inc.
Gilead Sciences, Inc
Italfarmaco S.P.A.
Karus Therapeutics Limited
Miragen Therapeutics, Inc
Zydus Cadila Incyte Corp.
Otsuka America Pharmaceutical, Inc. Pharmaclon
Teva Pharmaceuticals Inc.
Schering-Plough
GNC Vector
Alfarm
Merk and Co. Inc.
Pfizer.
Novartis AG
Bayer AG
Mylan N.V
GlaxosmithKline plc
Outline of Major Chapters:
Chapter 1: Introduces the definition of Polycythemia Vera Treatment, market overview.
Chapter 2: Global Polycythemia Vera Treatment market size in revenue and volume.
Chapter 3: Detailed analysis of Polycythemia Vera Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Polycythemia Vera Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Polycythemia Vera Treatment capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Polycythemia Vera Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Polycythemia Vera Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Polycythemia Vera Treatment Overall Market Size
2.1 Global Polycythemia Vera Treatment Market Size: 2022 VS 2029
2.2 Global Polycythemia Vera Treatment Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Polycythemia Vera Treatment Sales: 2018-2029
3 Company Landscape
3.1 Top Polycythemia Vera Treatment Players in Global Market
3.2 Top Global Polycythemia Vera Treatment Companies Ranked by Revenue
3.3 Global Polycythemia Vera Treatment Revenue by Companies
3.4 Global Polycythemia Vera Treatment Sales by Companies
3.5 Global Polycythemia Vera Treatment Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Polycythemia Vera Treatment Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Polycythemia Vera Treatment Product Type
3.8 Tier 1, Tier 2 and Tier 3 Polycythemia Vera Treatment Players in Global Market
3.8.1 List of Global Tier 1 Polycythemia Vera Treatment Companies
3.8.2 List of Global Tier 2 and Tier 3 Polycythemia Vera Treatment Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Polycythemia Vera Treatment Market Size Markets, 2022 & 2029
4.1.2 Antimetabolite
4.1.3 Inhibitors
4.1.4 Alpha Interferon
4.1.5 Others
4.2 By Type – Global Polycythemia Vera Treatment Revenue & Forecasts
4.2.1 By Type – Global Polycythemia Vera Treatment Revenue, 2018-2023
4.2.2 By Type – Global Polycythemia Vera Treatment Revenue, 2024-2029
4.2.3 By Type – Global Polycythemia Vera Treatment Revenue Market Share, 2018-2029
4.3 By Type – Global Polycythemia Vera Treatment Sales & Forecasts
4.3.1 By Type – Global Polycythemia Vera Treatment Sales, 2018-2023
4.3.2 By Type – Global Polycythemia Vera Treatment Sales, 2024-2029
4.3.3 By Type – Global Polycythemia Vera Treatment Sales Market Share, 2018-2029
4.4 By Type – Global Polycythemia Vera Treatment Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Polycythemia Vera Treatment Market Size, 2022 & 2029
5.1.2 Hospital Pharmacies
5.1.3 Retail Pharmacies
5.1.4 Online Sales
5.2 By Application – Global Polycythemia Vera Treatment Revenue & Forecasts
5.2.1 By Application – Global Polycythemia Vera Treatment Revenue, 2018-2023
5.2.2 By Application – Global Polycythemia Vera Treatment Revenue, 2024-2029
5.2.3 By Application – Global Polycythemia Vera Treatment Revenue Market Share, 2018-2029
5.3 By Application – Global Polycythemia Vera Treatment Sales & Forecasts
5.3.1 By Application – Global Polycythemia Vera Treatment Sales, 2018-2023
5.3.2 By Application – Global Polycythemia Vera Treatment Sales, 2024-2029
5.3.3 By Application – Global Polycythemia Vera Treatment Sales Market Share, 2018-2029
5.4 By Application – Global Polycythemia Vera Treatment Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Polycythemia Vera Treatment Market Size, 2022 & 2029
6.2 By Region – Global Polycythemia Vera Treatment Revenue & Forecasts
6.2.1 By Region – Global Polycythemia Vera Treatment Revenue, 2018-2023
6.2.2 By Region – Global Polycythemia Vera Treatment Revenue, 2024-2029
6.2.3 By Region – Global Polycythemia Vera Treatment Revenue Market Share, 2018-2029
6.3 By Region – Global Polycythemia Vera Treatment Sales & Forecasts
6.3.1 By Region – Global Polycythemia Vera Treatment Sales, 2018-2023
6.3.2 By Region – Global Polycythemia Vera Treatment Sales, 2024-2029
6.3.3 By Region – Global Polycythemia Vera Treatment Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Polycythemia Vera Treatment Revenue, 2018-2029
6.4.2 By Country – North America Polycythemia Vera Treatment Sales, 2018-2029
6.4.3 US Polycythemia Vera Treatment Market Size, 2018-2029
6.4.4 Canada Polycythemia Vera Treatment Market Size, 2018-2029
6.4.5 Mexico Polycythemia Vera Treatment Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Polycythemia Vera Treatment Revenue, 2018-2029
6.5.2 By Country – Europe Polycythemia Vera Treatment Sales, 2018-2029
6.5.3 Germany Polycythemia Vera Treatment Market Size, 2018-2029
6.5.4 France Polycythemia Vera Treatment Market Size, 2018-2029
6.5.5 U.K. Polycythemia Vera Treatment Market Size, 2018-2029
6.5.6 Italy Polycythemia Vera Treatment Market Size, 2018-2029
6.5.7 Russia Polycythemia Vera Treatment Market Size, 2018-2029
6.5.8 Nordic Countries Polycythemia Vera Treatment Market Size, 2018-2029
6.5.9 Benelux Polycythemia Vera Treatment Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Polycythemia Vera Treatment Revenue, 2018-2029
6.6.2 By Region – Asia Polycythemia Vera Treatment Sales, 2018-2029
6.6.3 China Polycythemia Vera Treatment Market Size, 2018-2029
6.6.4 Japan Polycythemia Vera Treatment Market Size, 2018-2029
6.6.5 South Korea Polycythemia Vera Treatment Market Size, 2018-2029
6.6.6 Southeast Asia Polycythemia Vera Treatment Market Size, 2018-2029
6.6.7 India Polycythemia Vera Treatment Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Polycythemia Vera Treatment Revenue, 2018-2029
6.7.2 By Country – South America Polycythemia Vera Treatment Sales, 2018-2029
6.7.3 Brazil Polycythemia Vera Treatment Market Size, 2018-2029
6.7.4 Argentina Polycythemia Vera Treatment Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Polycythemia Vera Treatment Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Polycythemia Vera Treatment Sales, 2018-2029
6.8.3 Turkey Polycythemia Vera Treatment Market Size, 2018-2029
6.8.4 Israel Polycythemia Vera Treatment Market Size, 2018-2029
6.8.5 Saudi Arabia Polycythemia Vera Treatment Market Size, 2018-2029
6.8.6 UAE Polycythemia Vera Treatment Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 ANP Technologies, INC.
7.1.1 ANP Technologies, INC. Company Summary
7.1.2 ANP Technologies, INC. Business Overview
7.1.3 ANP Technologies, INC. Polycythemia Vera Treatment Major Product Offerings
7.1.4 ANP Technologies, INC. Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.1.5 ANP Technologies, INC. Key News & Latest Developments
7.2 Bristol-Myers Squibb Company
7.2.1 Bristol-Myers Squibb Company Company Summary
7.2.2 Bristol-Myers Squibb Company Business Overview
7.2.3 Bristol-Myers Squibb Company Polycythemia Vera Treatment Major Product Offerings
7.2.4 Bristol-Myers Squibb Company Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.2.5 Bristol-Myers Squibb Company Key News & Latest Developments
7.3 F. Hoffmann-La Roche Ltd.
7.3.1 F. Hoffmann-La Roche Ltd. Company Summary
7.3.2 F. Hoffmann-La Roche Ltd. Business Overview
7.3.3 F. Hoffmann-La Roche Ltd. Polycythemia Vera Treatment Major Product Offerings
7.3.4 F. Hoffmann-La Roche Ltd. Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.3.5 F. Hoffmann-La Roche Ltd. Key News & Latest Developments
7.4 Galena Biopharma, Inc.
7.4.1 Galena Biopharma, Inc. Company Summary
7.4.2 Galena Biopharma, Inc. Business Overview
7.4.3 Galena Biopharma, Inc. Polycythemia Vera Treatment Major Product Offerings
7.4.4 Galena Biopharma, Inc. Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.4.5 Galena Biopharma, Inc. Key News & Latest Developments
7.5 Gilead Sciences, Inc
7.5.1 Gilead Sciences, Inc Company Summary
7.5.2 Gilead Sciences, Inc Business Overview
7.5.3 Gilead Sciences, Inc Polycythemia Vera Treatment Major Product Offerings
7.5.4 Gilead Sciences, Inc Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.5.5 Gilead Sciences, Inc Key News & Latest Developments
7.6 Italfarmaco S.P.A.
7.6.1 Italfarmaco S.P.A. Company Summary
7.6.2 Italfarmaco S.P.A. Business Overview
7.6.3 Italfarmaco S.P.A. Polycythemia Vera Treatment Major Product Offerings
7.6.4 Italfarmaco S.P.A. Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.6.5 Italfarmaco S.P.A. Key News & Latest Developments
7.7 Karus Therapeutics Limited
7.7.1 Karus Therapeutics Limited Company Summary
7.7.2 Karus Therapeutics Limited Business Overview
7.7.3 Karus Therapeutics Limited Polycythemia Vera Treatment Major Product Offerings
7.7.4 Karus Therapeutics Limited Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.7.5 Karus Therapeutics Limited Key News & Latest Developments
7.8 Miragen Therapeutics, Inc
7.8.1 Miragen Therapeutics, Inc Company Summary
7.8.2 Miragen Therapeutics, Inc Business Overview
7.8.3 Miragen Therapeutics, Inc Polycythemia Vera Treatment Major Product Offerings
7.8.4 Miragen Therapeutics, Inc Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.8.5 Miragen Therapeutics, Inc Key News & Latest Developments
7.9 Zydus Cadila Incyte Corp.
7.9.1 Zydus Cadila Incyte Corp. Company Summary
7.9.2 Zydus Cadila Incyte Corp. Business Overview
7.9.3 Zydus Cadila Incyte Corp. Polycythemia Vera Treatment Major Product Offerings
7.9.4 Zydus Cadila Incyte Corp. Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.9.5 Zydus Cadila Incyte Corp. Key News & Latest Developments
7.10 Otsuka America Pharmaceutical, Inc. Pharmaclon
7.10.1 Otsuka America Pharmaceutical, Inc. Pharmaclon Company Summary
7.10.2 Otsuka America Pharmaceutical, Inc. Pharmaclon Business Overview
7.10.3 Otsuka America Pharmaceutical, Inc. Pharmaclon Polycythemia Vera Treatment Major Product Offerings
7.10.4 Otsuka America Pharmaceutical, Inc. Pharmaclon Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.10.5 Otsuka America Pharmaceutical, Inc. Pharmaclon Key News & Latest Developments
7.11 Teva Pharmaceuticals Inc.
7.11.1 Teva Pharmaceuticals Inc. Company Summary
7.11.2 Teva Pharmaceuticals Inc. Polycythemia Vera Treatment Business Overview
7.11.3 Teva Pharmaceuticals Inc. Polycythemia Vera Treatment Major Product Offerings
7.11.4 Teva Pharmaceuticals Inc. Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.11.5 Teva Pharmaceuticals Inc. Key News & Latest Developments
7.12 Schering-Plough
7.12.1 Schering-Plough Company Summary
7.12.2 Schering-Plough Polycythemia Vera Treatment Business Overview
7.12.3 Schering-Plough Polycythemia Vera Treatment Major Product Offerings
7.12.4 Schering-Plough Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.12.5 Schering-Plough Key News & Latest Developments
7.13 GNC Vector
7.13.1 GNC Vector Company Summary
7.13.2 GNC Vector Polycythemia Vera Treatment Business Overview
7.13.3 GNC Vector Polycythemia Vera Treatment Major Product Offerings
7.13.4 GNC Vector Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.13.5 GNC Vector Key News & Latest Developments
7.14 Alfarm
7.14.1 Alfarm Company Summary
7.14.2 Alfarm Business Overview
7.14.3 Alfarm Polycythemia Vera Treatment Major Product Offerings
7.14.4 Alfarm Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.14.5 Alfarm Key News & Latest Developments
7.15 Merk and Co. Inc.
7.15.1 Merk and Co. Inc. Company Summary
7.15.2 Merk and Co. Inc. Business Overview
7.15.3 Merk and Co. Inc. Polycythemia Vera Treatment Major Product Offerings
7.15.4 Merk and Co. Inc. Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.15.5 Merk and Co. Inc. Key News & Latest Developments
7.16 Pfizer.
7.16.1 Pfizer. Company Summary
7.16.2 Pfizer. Business Overview
7.16.3 Pfizer. Polycythemia Vera Treatment Major Product Offerings
7.16.4 Pfizer. Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.16.5 Pfizer. Key News & Latest Developments
7.17 Novartis AG
7.17.1 Novartis AG Company Summary
7.17.2 Novartis AG Business Overview
7.17.3 Novartis AG Polycythemia Vera Treatment Major Product Offerings
7.17.4 Novartis AG Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.17.5 Novartis AG Key News & Latest Developments
7.18 Bayer AG
7.18.1 Bayer AG Company Summary
7.18.2 Bayer AG Business Overview
7.18.3 Bayer AG Polycythemia Vera Treatment Major Product Offerings
7.18.4 Bayer AG Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.18.5 Bayer AG Key News & Latest Developments
7.19 Mylan N.V
7.19.1 Mylan N.V Company Summary
7.19.2 Mylan N.V Business Overview
7.19.3 Mylan N.V Polycythemia Vera Treatment Major Product Offerings
7.19.4 Mylan N.V Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.19.5 Mylan N.V Key News & Latest Developments
7.20 GlaxosmithKline plc
7.20.1 GlaxosmithKline plc Company Summary
7.20.2 GlaxosmithKline plc Business Overview
7.20.3 GlaxosmithKline plc Polycythemia Vera Treatment Major Product Offerings
7.20.4 GlaxosmithKline plc Polycythemia Vera Treatment Sales and Revenue in Global (2018-2023)
7.20.5 GlaxosmithKline plc Key News & Latest Developments
8 Global Polycythemia Vera Treatment Production Capacity, Analysis
8.1 Global Polycythemia Vera Treatment Production Capacity, 2018-2029
8.2 Polycythemia Vera Treatment Production Capacity of Key Manufacturers in Global Market
8.3 Global Polycythemia Vera Treatment Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Polycythemia Vera Treatment Supply Chain Analysis
10.1 Polycythemia Vera Treatment Industry Value Chain
10.2 Polycythemia Vera Treatment Upstream Market
10.3 Polycythemia Vera Treatment Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Polycythemia Vera Treatment Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 真性多血症治療薬のグローバル市場展望 2023年-2029年：ダサチニブ、イデラリシブ、ジビノスタット、M-009、他
  • 世界の真性多血症治療法市場2022年：市場規模予測（～2028年）
  • IgA腎症治療薬のグローバル市場展望 2023年-2029年：第I相、第II相、第III相
  • 皮膚糸状菌症治療のグローバル市場展望 2023年-2029年：Rx、OTC
  • サラセミア治療のグローバル市場展望 2023年-2029年：DFO、DFP、DFX、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23LY8574 )"真性赤血球増加症治療のグローバル市場展望 2023年-2029年：代謝拮抗剤、阻害剤、αインターフェロン、その他" (英文：Polycythemia Vera Treatment Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。